

# Alnylam Assist™ Offers a Wide Range of Services to Guide Patients Through Treatment

**A team of experts provides a number of personalized services throughout the treatment process**



## A DEDICATED CASE MANAGER

Experienced in helping individuals get started on treatment and providing ongoing support. They help patients understand insurance coverage, financial assistance options for eligible\* patients, as well as provide educational resources.



## SUPPORT AFFORDING MEDICINE\*

For commercially-insured patients, the **Commercial Copay Program** ensures that patients pay \$0 out-of-pocket costs for Alnylam therapies. For uninsured-patients, the **Patient Assistance Program** may be able to provide Alnylam therapies at no cost.



## SCHEDULING TREATMENT & DELIVERY

The Alnylam Assist™ team will help facilitate acquisition of the medication for the patient via specialty distributor or specialty pharmacy.



Alnylam's **Quick Start Program** supports commercially insured patients who may experience delays in coverage by providing up to 3 treatments at no cost.

## Alnylam Assist™ Case Managers Are There at Every Step



Connects patients with a **Patient Education Liaison**, who can answer questions about the disease and treatment



Provides patients and their HCPs with a comprehensive **benefit verification** within 2 business days of receiving the Alnylam Assist™ Start Form



Works with a **Field Reimbursement Director** to provide education about billing, coding, and the reimbursement process

**Questions? Call 1-833-256-2748 or visit [AlnylamAssist.com](https://AlnylamAssist.com)**

\*Individuals must meet specified criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time. Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for Alnylam's Quick Start Program, Commercial Copay Program, or Patient Assistance Program.



Alnylam Assist is a trademark of Alnylam Pharmaceuticals, Inc.  
© 2019 Alnylam Pharmaceuticals, Inc. All rights reserved. TTR02-USA-00126-042018\_V2

